enGene (ENGN) Competitors $3.88 +0.14 (+3.74%) As of 07/3/2025 03:56 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ENGN vs. XERS, CRON, MENS, REPL, VIR, SION, GYRE, PHAT, ANAB, and IMTXShould you be buying enGene stock or one of its competitors? The main competitors of enGene include Xeris Biopharma (XERS), Cronos Group (CRON), Jyong Biotech (MENS), Replimune Group (REPL), Vir Biotechnology (VIR), Sionna Therapeutics (SION), Gyre Therapeutics (GYRE), Phathom Pharmaceuticals (PHAT), AnaptysBio (ANAB), and Immatics (IMTX). These companies are all part of the "pharmaceutical products" industry. enGene vs. Its Competitors Xeris Biopharma Cronos Group Jyong Biotech Replimune Group Vir Biotechnology Sionna Therapeutics Gyre Therapeutics Phathom Pharmaceuticals AnaptysBio Immatics Xeris Biopharma (NASDAQ:XERS) and enGene (NASDAQ:ENGN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership. Do institutionals & insiders hold more shares of XERS or ENGN? 42.8% of Xeris Biopharma shares are held by institutional investors. Comparatively, 64.2% of enGene shares are held by institutional investors. 6.5% of Xeris Biopharma shares are held by company insiders. Comparatively, 10.4% of enGene shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the media refer more to XERS or ENGN? In the previous week, enGene had 15 more articles in the media than Xeris Biopharma. MarketBeat recorded 16 mentions for enGene and 1 mentions for Xeris Biopharma. Xeris Biopharma's average media sentiment score of 0.67 beat enGene's score of -0.30 indicating that Xeris Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xeris Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive enGene 0 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 2 Negative mention(s) 4 Very Negative mention(s) Neutral Which has more risk & volatility, XERS or ENGN? Xeris Biopharma has a beta of 0.66, suggesting that its stock price is 34% less volatile than the S&P 500. Comparatively, enGene has a beta of -0.42, suggesting that its stock price is 142% less volatile than the S&P 500. Which has stronger valuation & earnings, XERS or ENGN? Xeris Biopharma has higher revenue and earnings than enGene. Xeris Biopharma is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXeris Biopharma$203.07M3.66-$54.84M-$0.30-15.85enGeneN/AN/A-$55.14M-$1.65-2.35 Do analysts rate XERS or ENGN? Xeris Biopharma presently has a consensus price target of $6.25, suggesting a potential upside of 31.44%. enGene has a consensus price target of $23.29, suggesting a potential upside of 500.15%. Given enGene's stronger consensus rating and higher possible upside, analysts plainly believe enGene is more favorable than Xeris Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xeris Biopharma 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83enGene 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00 Is XERS or ENGN more profitable? enGene has a net margin of 0.00% compared to Xeris Biopharma's net margin of -20.25%. Xeris Biopharma's return on equity of 0.00% beat enGene's return on equity.Company Net Margins Return on Equity Return on Assets Xeris Biopharma-20.25% N/A -12.07% enGene N/A -32.60%-28.26% SummaryenGene beats Xeris Biopharma on 9 of the 16 factors compared between the two stocks. Get enGene News Delivered to You Automatically Sign up to receive the latest news and ratings for ENGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ENGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENGN vs. The Competition Export to ExcelMetricenGeneMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$194.20M$2.89B$5.53B$9.04BDividend YieldN/A2.44%5.24%4.01%P/E Ratio-2.3521.7127.6320.25Price / SalesN/A281.07417.36118.17Price / CashN/A42.7336.8958.07Price / Book0.877.518.035.67Net Income-$55.14M-$55.14M$3.18B$249.21M7 Day Performance6.01%4.61%2.91%3.28%1 Month Performance7.18%4.72%3.72%5.55%1 Year Performance-57.60%5.92%35.14%21.08% enGene Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENGNenGene2.6403 of 5 stars$3.88+3.7%$23.29+500.1%-56.8%$194.20MN/A-2.3531XERSXeris Biopharma3.9038 of 5 stars$4.67-0.6%$6.25+33.8%+128.6%$735.01M$222.55M-15.57290Positive NewsCRONCronos Group2.2939 of 5 stars$1.91+0.5%N/A-12.1%$732.80M$117.61M14.69450News CoverageMENSJyong BiotechN/A$8.50-10.5%N/AN/A$722.26MN/A0.0031REPLReplimune Group4.1867 of 5 stars$9.29-0.4%$20.83+124.3%+16.8%$719.22MN/A-3.03210News CoverageAnalyst ForecastVIRVir Biotechnology3.3686 of 5 stars$5.04-2.5%$32.86+551.9%-37.3%$714.69M$74.21M-1.19580News CoverageInsider TradeSIONSionna TherapeuticsN/A$17.35+9.5%$38.50+121.9%N/A$698.92MN/A0.0035Positive NewsInsider TradeGYREGyre Therapeutics0.0783 of 5 stars$7.35-0.9%N/A-30.5%$695.68M$105.76M367.6840PHATPhathom Pharmaceuticals3.5928 of 5 stars$9.59-1.5%$17.50+82.5%-14.5%$679.99M$55.25M-1.83110ANABAnaptysBio2.3466 of 5 stars$22.20-1.2%$42.38+90.9%-3.4%$660.18M$91.28M-4.58100News CoveragePositive NewsInsider TradeIMTXImmatics2.4608 of 5 stars$5.38-0.9%$14.67+172.6%-52.3%$660.02M$168.65M-31.65260Positive News Related Companies and Tools Related Companies XERS Competitors CRON Competitors MENS Competitors REPL Competitors VIR Competitors SION Competitors GYRE Competitors PHAT Competitors ANAB Competitors IMTX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ENGN) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding enGene Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share enGene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ENGN Stock Alerts